What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Kevin R. Flaherty mainly focuses on Idiopathic pulmonary fibrosis, Internal medicine, Pulmonary fibrosis, Usual interstitial pneumonia and Idiopathic interstitial pneumonia.
He combines subjects such as Respiratory disease, Surgery, Pathology and Intensive care medicine with his study of Idiopathic pulmonary fibrosis.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Placebo.
The study incorporates disciplines such as Intensive care and Pulmonary function testing in addition to Pulmonary fibrosis.
He interconnects High-resolution computed tomography and Lung biopsy in the investigation of issues within Idiopathic interstitial pneumonia.
His research investigates the connection between Interstitial lung disease and topics such as Guideline that intersect with problems in Evidence-based practice and Evidence-based medicine.
His most cited work include:
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management (4402 citations)
- Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (2009 citations)
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias (1870 citations)
What are the main themes of his work throughout his whole career to date?
Kevin R. Flaherty focuses on Idiopathic pulmonary fibrosis, Internal medicine, Pathology, Interstitial lung disease and Lung.
His studies deal with areas such as Pulmonary fibrosis, Clinical trial, Vital capacity and Intensive care medicine as well as Idiopathic pulmonary fibrosis.
His research in Internal medicine intersects with topics in Gastroenterology and Cardiology.
His Interstitial lung disease study combines topics from a wide range of disciplines, such as Connective tissue disease and Hypersensitivity pneumonitis.
He has researched Lung in several fields, including Fibrosis and Immunology.
His FEV1/FVC ratio research is multidisciplinary, incorporating perspectives in Diffusing capacity, Placebo and Surgery.
He most often published in these fields:
- Idiopathic pulmonary fibrosis (50.76%)
- Internal medicine (45.57%)
- Pathology (21.41%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (45.57%)
- Idiopathic pulmonary fibrosis (50.76%)
- Interstitial lung disease (21.41%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Idiopathic pulmonary fibrosis, Interstitial lung disease, Nintedanib and Gastroenterology.
His research integrates issues of Placebo and Placebo-controlled study in his study of Internal medicine.
His Idiopathic pulmonary fibrosis research includes elements of Pulmonary fibrosis, Vital capacity, Radiology and Clinical trial.
He has included themes like Blood drawing, Randomized controlled trial, Pirfenidone and Intensive care medicine in his Clinical trial study.
His Idiopathic interstitial pneumonia study in the realm of Interstitial lung disease connects with subjects such as Multidisciplinary approach.
His Nintedanib research incorporates elements of Discontinuation and Cardiology.
Between 2018 and 2021, his most popular works were:
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (300 citations)
- Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. (64 citations)
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial (55 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His primary areas of investigation include Idiopathic pulmonary fibrosis, Internal medicine, FEV1/FVC ratio, Interstitial lung disease and Clinical trial.
His Idiopathic pulmonary fibrosis research includes themes of Pulmonary fibrosis, Vital capacity, Radiology and DLCO.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His work carried out in the field of FEV1/FVC ratio brings together such families of science as Placebo and Hypersensitivity pneumonitis.
The Usual interstitial pneumonia research Kevin R. Flaherty does as part of his general Interstitial lung disease study is frequently linked to other disciplines of science, such as Routine care and Patient management, therefore creating a link between diverse domains of science.
His study looks at the intersection of Clinical trial and topics like Intensive care medicine with Disease, Rare disease, Exacerbation, Extracorporeal membrane oxygenation and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
